Trial Profile
A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Gastric cancer; Lung cancer; Malignant thymoma; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 13 Sep 2022 Results from NCT02267967, NCT02588170, NCT02589821; assessing whether radiomics-based machine learning model could predict treatment responses in patients with advanced NET, presented at the 47th European Society for Medical Oncology Congress
- 21 Feb 2018 Status changed from active, no longer recruiting to completed.
- 19 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.